Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | PDCD1LG2 | Q9BQ51 | 1/20 | 0.37 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.37 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.37 |
| ▸ | CDK9 | P50750 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19087064 | 0.89 | PDCD1LG2 (0.41) | PDCD1LG2CD274CYP2C9EPHX2MAP4K4 | |
| SCHEMBL7920351 | 0.89 | PDCD1LG2 (0.41) | PDCD1LG2CD274CYP2C9EPHX2MAP4K4 | |
| SCHEMBL14250161 | 0.82 | — | — | |
| SCHEMBL30339210 | 0.82 | — | — | |
| SCHEMBL28262276 | 0.81 | MAP4K4 (0.39) | PDCD1LG2CD274CYP2C9EPHX2MAP4K4 | |
| Oxalic Acid SCHEMBL9459120 | 0.81 | CYP2C9 (0.46) | KDM4EPDCD1LG2CD274CYP2C9EPHX2 | |
| SCHEMBL12049777 | 0.81 | PDE9A (0.37) | PDCD1LG2CD274CYP2C9EPHX2MAP4K4 | |
| SCHEMBL16218245 | 0.81 | PARP1 (0.41) | PDCD1LG2CD274CYP2C9EPHX2MAP4K4 | |
| SCHEMBL15448220 | 0.81 | PDCD1LG2 (0.35) | KDM4EPDCD1LG2CD274CYP2C9EPHX2 | |
| SCHEMBL12090384 | 0.80 | MAP4K4 (0.46) | CYP2C9EPHX2MAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1560817-A1 | METHODS AND COMPOSITIONS OF NOVEL TRIAZINE COMPOUNDS | Reddy US Therapeutics, Inc. (US) | 2005-08-10 | — | — | EP | claimed |
| WO-2004026844-A9 | METHODS AND COMPOSITIONS OF NOVEL TRIAZINE COMPOUNDS | REDDY US THERAPEUTICS INC (US) | 2004-11-11 | — | — | WO | claimed |
| WO-2004026844-A1 | METHODS AND COMPOSITIONS OF NOVEL TRIAZINE COMPOUNDS | REDDY US THERAPEUTICS, INC. (US) | 2004-04-01 | — | — | WO | claimed |
| WO-2020247298-A2 | 1-PYRAZOLYL, 5-, 6- DISUBSTITUTED INDAZOLE DERIVATIVES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | MERCK SHARP & DOHME CORP. (US) | 2020-12-10 | — | — | WO | disclosed |
| US-20190161499-A1 | PESTICIDALLY ACTIVE 1,2,4-TRIAZOLE DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2019-05-30 | — | — | US | disclosed |
| US-10301267-B2 | Compounds | ASTRAZENECA AB (SE) | 2019-05-28 | — | — | US | disclosed |
| EP-2773207-B1 | AMINOPYRIMIDINONES AS INTERLEUKIN RECEPTOR-ASSOCIATED KINASE INHIBITORS | MERCK SHARP & DOHME (US) | 2018-03-07 | — | — | EP | disclosed |
| US-20170260143-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2017-09-14 | — | — | US | disclosed |
| US-9688640-B2 | Methods of treating cancer with a pyrazole derivative | ASTRAZENECA AB (SE) | 2017-06-27 | — | — | US | disclosed |
| US-9221809-B2 | Aminopyrimidinones as interleukin receptor-associated kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-12-29 | — | — | US | disclosed |
| US-20150299134-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2015-10-22 | — | — | US | disclosed |
| US-9115101-B2 | Aryl sultam derivatives as RORc modulators | GENENTECH, INC. (US) | 2015-08-25 | — | — | US | disclosed |
| US-20140329799-A1 | AMINOPYRIMIDINONES AS INTERLEUKIN RECEPTOR-ASSOCIATED KINASE INHIBITORS | MERCK SHARP & DOHME LLC | 2014-11-06 | — | — | US | disclosed |
| US-20140066455-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2014-03-06 | — | — | US | disclosed |
| US-20140031330-A1 | ARYL SULTAM DERIVATIVES AS RORc MODULATORS | GENENTECH INC (US) | 2014-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190161499-A1 | PESTICIDALLY ACTIVE 1,2,4-TRIAZOLE DERIVATIVES | ACHE, AADAC, ATL3 | KDM4E 1505/4885ALDH1A1 533/4885PDCD1LG2 2121/4885 |
| US-10301267-B2 | Compounds | SLC10A1, CYP11B1, ABCB11 | KDM4E 2865/4885ALDH1A1 78/4885PDCD1LG2 4613/4885 |
| US-20140329799-A1 | AMINOPYRIMIDINONES AS INTERLEUKIN RECEPTOR-ASSOCIATED KINASE INHIBITORS | IRAK4, IRAK1, IRAK2 | KDM4E 260/4885ALDH1A1 831/4885PDCD1LG2 1790/4885 |
| US-20140066455-A1 | NOVEL COMPOUNDS | SLC10A1, ABCB11, CYP11B1 | KDM4E 3393/4885ALDH1A1 338/4885PDCD1LG2 4588/4885 |
| US-20140031330-A1 | ARYL SULTAM DERIVATIVES AS RORc MODULATORS | RORC, RORB, RORA | KDM4E 2084/4885ALDH1A1 451/4885PDCD1LG2 4055/4885 |
| US-20170260143-A1 | NOVEL COMPOUNDS | SLC10A1, ABCB11, CYP11B1 | KDM4E 3393/4885ALDH1A1 338/4885PDCD1LG2 4588/4885 |
| US-20150299134-A1 | NOVEL COMPOUNDS | SLC10A1, ABCB11, CYP11B1 | KDM4E 3393/4885ALDH1A1 338/4885PDCD1LG2 4588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.